Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment

Annals of the Rheumatic Diseases · Published 2026-05-14 · DOI 10.1016/j.ard.2026.03.032

Free full text

Authors (8)

Alexis Ogdie, Philip J. Mease, Emmanouil Rampakakis, Karissa Lozenski, Mohamed Sharaf, Elizabeth Adamson, Helena Marzo-Ortega, Laure Gossec

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ogdie, A., Mease, P., Rampakakis, E., et al. (2026). Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.03.032

Related articles

• Response to correspondence on ‘Final validation of the hierarchical framework for outcomes in axial spondyloarthritis: longitudinal determinants of health-related quality of life’ · Annals of the Rheumatic Diseases · 2026 · Same journal
• Mitochondrial-impaired ductal epithelium fuels TLS formation in Sjögren’s disease · Annals of the Rheumatic Diseases · 2026 · Same journal
• Development and validation of quality indicators for lupus nephritis, based on the 2025 EULAR recommendations: adherence trends and impact on clinical outcomes · Annals of the Rheumatic Diseases · 2026 · Same journal
• Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis · Annals of the Rheumatic Diseases · 2026 · Same journal
• Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries · Annals of the Rheumatic Diseases · 2026 · Same journal
• Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma · Annals of the Rheumatic Diseases · 2026 · Same journal
• Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project · Annals of the Rheumatic Diseases · 2026 · Same journal
• Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series · Annals of the Rheumatic Diseases · 2026 · Same journal
• Symmetrical dimethylarginine as the central antigenic determinant of anti-Smith autoantibodies in systemic lupus erythematosus · Annals of the Rheumatic Diseases · 2026 · Same journal
• A novel STAT4 gain-of-function variant defines a monogenic form of juvenile-onset systemic lupus erythematosus · Annals of the Rheumatic Diseases · 2026 · Same journal